World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
29419
World Ranking
14982
National Ranking
791

Overview

Juris J. Meier is affiliated with Ruhr University Bochum in Germany and has contributed extensively to the field of medical research, focusing primarily on diabetes and metabolism. Their research encompasses several subfields, including endocrinology, molecular biology, surgery, pharmacology, and genetics.

Their work is mainly centered on the management and treatment of diabetes, with a particular emphasis on diabetes treatment and management, metabolism, and cancer, as well as pancreatic function related to diabetes. Other research topics covered include pharmacology and obesity treatment, diet and metabolism studies, and diabetes-associated disorders.

Notable recent publications by Juris J. Meier include:

  • Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation, 2021, Frontiers in Endocrinology
  • GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art, 2020, Molecular Metabolism
  • Treatment of type 2 diabetes: challenges, hopes, and anticipated successes, 2021, The Lancet Diabetes & Endocrinology
  • Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme, 2020, Diabetes Obesity and Metabolism
  • Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis, 2020, Diabetes Care

Juris J. Meier frequently collaborates with other researchers in the field. Notable coauthors include:

  • Michael A. Nauck
  • Daniel R. Quast
  • Richard E. Pratley
  • Christoph Kapitza
  • Nina Schenker

The researcher has published multiple papers in several key journals that focus on diabetes and metabolism. These venues include:

  • Diabetes Obesity and Metabolism
  • Diabetes
  • Diabetologie und Stoffwechsel
  • Diabetes Care
  • Experimental and Clinical Endocrinology & Diabetes

Juris J. Meier's work falls within the broader fields of medicine and biochemistry, genetics, and molecular biology, with the majority of publications contributing to medicine. Their research integrates clinical and molecular approaches to better understand and treat diabetes and associated metabolic disorders.

Best Publications

  • Glucagon-like peptide 1 (GLP-1)

    T.D. Müller;B. Finan;S.R. Bloom;D. D'Alessio

  • GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.

    Juris J. Meier

  • GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.

    Michael A. Nauck;Daniel R. Quast;Jakob Wefers;Juris J. Meier

  • β-Cell Replication Is the Primary Mechanism Subserving the Postnatal Expansion of β-Cell Mass in Humans

    Juris J. Meier;Alexandra E. Butler;Yoshifumi Saisho;Travis Monchamp

  • Incretin hormones: Their role in health and disease.

    Michael A. Nauck;Juris J. Meier

  • Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial

    Michael A. Nauck;Stefano Del Prato;Juris J. Meier;Santiago Durán-García

  • Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.

    Carolyn F. Deacon;Michael A. Nauck;Juris Meier;Katrin Hücking

  • Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration?

    J. J. Meier;A. Bhushan;A. E. Butler;R. A. Rizza

  • Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

    M. A. Nauck;I. Vardarli;C. F. Deacon;J. J. Holst

  • Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.

    Michael A. Nauck;Juris J. Meier;Matthew A. Cavender;Mirna Abd El Aziz

  • Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes

    Y. Saisho;A. E. Butler;J. J. Meier;T. Monchamp

  • Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes

    Juris J. Meier;Baptist Gallwitz;Stefan Salmen;Oliver Goetze

  • PREDICTORS OF INCRETIN CONCENTRATIONS IN SUBJECTS WITH NORMAL, IMPAIRED, AND DIABETIC GLUCOSE TOLERANCE

    Kirsten Vollmer;Jens J. Holst;Birgit Baller;Mark Ellrichmann

  • The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions

    Michael A Nauck;Juris J Meier

  • Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects

    Juris J. Meier;Michael A. Nauck;Daniel Kranz;Jens J. Holst

  • Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

    J. J. Meier;B. Gallwitz;N. Siepmann;J. J. Holst

  • Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

    Richard Pratley;Aslam Amod;Søren Tetens Hoff;Takashi Kadowaki

  • Glucagon‐like peptide 1(GLP‐1) in biology and pathology

    Juris J. Meier;Michael A. Nauck

  • Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans

    Michael A Nauck;Guido Kemmeries;Jens Juul Holst;Juris J Meier

  • Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

    J. J. Meier;A. Gethmann;O. Götze;B. Gallwitz

Frequent Co-Authors

Michael A. Nauck
Michael A. Nauck Ruhr University Bochum
Jens J. Holst
Jens J. Holst University of Copenhagen
Carolyn F. Deacon
Carolyn F. Deacon University of Copenhagen
Peter C. Butler
Peter C. Butler University of California, Los Angeles
Andrea Tannapfel
Andrea Tannapfel Leipzig University
Robert A. Rizza
Robert A. Rizza Mayo Clinic
Michael Horowitz
Michael Horowitz University of Adelaide
Julio Rosenstock
Julio Rosenstock The University of Texas Southwestern Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine opens the door to many alternative and related degree options beyond the traditional M.D. pathway. Today, flexible online programs make these opportunities more accessible than ever, allowing you to further your education while balancing work and life commitments.

For nursing professionals, advancing from registered nurse to nurse practitioner is a sought-after option. RN to NP bridge programs offer a streamlined path for those holding an associate’s degree, enabling career advancement into advanced practice roles. Alternatively, nurses looking to earn their bachelor’s without attending clinicals can explore RN to BSN programs no clinicals.

If you're interested in the intersection of healthcare and business, consider online MHA programs that prepare students for leadership roles in healthcare management. Or, if nutrition and wellness align more with your career goals, the best online nutrition degree programs open pathways to becoming a nutritionist or dietitian.

Each of these online degrees offers a unique career trajectory within healthcare, catering to diverse interests and helping fill critical roles in the industry.

Best Scientists Citing Juris J. Meier

Trending Scientists

Recently Published Articles